Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trial
Brian G. Feagan(Western University), Dermot McGovern(Salford Royal NHS Foundation Trust), Ernesto J. Muñoz‐Elías(Merck & Co., Inc., Rahway, NJ, USA (United States)), Marla C. Dubinsky(Icahn School of Medicine at Mount Sinai), Jiandong Lu(Guangzhou University of Chinese Medicine), Fadi Towfic, Deanna D. Nguyen, Janine Bilsborough(Cedars-Sinai Medical Center), Jarosław Kierkuś(Children's Memorial Health Institute), Marek Woynarowski(Yale University), Stephan R. Targan(Cedars-Sinai Medical Center), Ronald R. Marchelletta(Merck & Co., Inc., Rahway, NJ, USA (United States)), Allison Luo(Merck & Co., Inc., Rahway, NJ, USA (United States)), Houssam Al Kharrat, Aaron DuVall, João Sabino(KU Leuven), Olivier Laurent(University of California, Irvine), Corey A. Siegel(Dartmouth–Hitchcock Medical Center), Yong Wang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Bruce E Sands, Randy Longman(Cornell University), Mark Yen(Merck & Co., Inc., Rahway, NJ, USA (United States)), J. Anderson(AbbVie (United States))
Cited by 28
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
A Genome-Wide Association Study Identifies <i>IL23R</i> as an Inflammatory Bowel Disease Gene
|Science|2006|3k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k